Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics11The Eye and Ear Foundation of Pittsburgh (Pittsburgh, PA) was given a core grant for Vision Research EY 08098 and Research to Prevent Blindness. The first author (R.M.) was granted travel support for ARVO 2001 in Fort Lauderdale, FL by Alcon (Fort Worth, TX).

Leibowitz, 1991, Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis, Am J Ophthalmol, 112, 34S O’Brien, 1995, Efficacy of ofloxacin versus cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group, Arch Ophthalmol, 113, 1257, 10.1001/archopht.1995.01100100045026 Goldstein, 1999, Emerging fluoroquinolone resistance in bacterial keratitis, Ophthalmology, 106, 1313, 10.1016/S0161-6420(99)00716-2 Chaudhry, 1999, Emerging ciprofloxacin-resistant Pseudomonas aeruginosa, Am J Ophthalmol, 128, 509, 10.1016/S0002-9394(99)00196-8 2000, Vol. 20 Stahlmann, 1999, Toxicity of quinolones, Drugs, 58, 37, 10.2165/00003495-199958002-00007 Domagala, 1994, Structure-activity and structure-side-effect relationships for the quinolone antibacterial, J Antimicrob Chem, 33, 685, 10.1093/jac/33.4.685 Drlica, 2001, A strategy for fighting antibiotic resistance, ASM News, 67, 27 Courvalin, 2000, The influence of antibacterial mechanisms of action on the emergence, dissemination, and prevention of resistance, Ochsner Clin Symp Resist Use Misuse Antimicrob Ther, 15 Stroman, 2001, Moxifloxacin activity against quinolone resistant Staphylococcal ocular isolates, Invest Ophthalmol Vis Sci, 42, 1377